![]() |
||||||||||||||||
|
![]() |
![]() |
||||||||||||||
News & EventsPOSITIVE RESULTS IN INFLAMMATORY EYE DISEASE TREATMENTXigen announces the online publication of successful Phase II results for its lead compound Brimapitide (XG-102) in the American Journal of Ophthalmology. - January 2017
|
![]() |
|||||||||||||||
![]() |
© Xigen 2016 | ![]() |
||||||||||||||
![]() |
![]() |
![]() |
![]() |